课题基金 / 基金详情

Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial

Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
醛固酮拮抗剂在终末期肾病中保护心脏(第 2 阶段)试验
批准号:
310286
负责人:
Walsh Michael W
金额:
$7.29万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2014
资助国家:
加拿大
项目状态:
已结题
起止时间:
2014-03-01 至 2015-03-01

项目摘要

项目成果

Walsh Michael W的其他基金

相似基金

相关文献

中文摘要
翻译
40%需要透析治疗肾衰竭的患者在三年内死亡,主要原因是心脏病。螺内酯是一种药物,在减少心力衰竭患者的心脏相关死亡和住院治疗方面非常有效,
英文摘要
Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. Spironlactone is a drug that is very effective at reducing heart related deaths and hospitalizations in patients with heart failure that
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glucocorticoids or Avacopan in peopLe with high-risk renal Anti-Neutrophil cytoplasm antibody associated vasculitis Trial (GALANT) - Pilot
  • 批准号:
    489796
  • 项目类别:
    Operating Grants
  • 资助金额:
    $37.9万
  • 财政年份:
    2023
  • 负责人:
    Walsh Michael W
  • 依托单位:
Aldosterone blockade for Health Improvement Evaluation in End-stage kidney disease: Extension
  • 批准号:
    461992
  • 项目类别:
    Operating Grants
  • 资助金额:
    $88.05万
  • 财政年份:
    2022
  • 负责人:
    Walsh Michael W
  • 依托单位:
Protection of the heart with aldosterone antagonism in end-stage renal disease (PHASE 2) Trial
  • 批准号:
    333015
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis: extended follow-up of a randomized controlled trial
  • 批准号:
    322606
  • 项目类别:
    Operating Grants
  • 资助金额:
    $24.76万
  • 财政年份:
    2015
  • 负责人:
    Walsh Michael W
  • 依托单位:
海外基金